PMID,Title,Journal,Year
37898288,Canagliflozin ameliorates ulcerative colitis via regulation of TLR4/MAPK/NF-kappaB and Nrf2/PPAR-gamma/SIRT1 signaling pathways.,European journal of pharmacology,2023
37086302,Empagliflozin attenuates intestinal inflammation through suppression of nitric oxide synthesis and myeloperoxidase activity in in vitro and in vivo models of colitis.,Inflammopharmacology,2024
36076534,Canagliflozin-loaded chitosan-hyaluronic acid microspheres modulate AMPK/NF-kappaB/NLRP3 axis: A new paradigm in the rectal therapy of ulcerative colitis.,Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,2022
34328119,"Canagliflozin, an SGLT-2 inhibitor, ameliorates acetic acid-induced colitis in rats through targeting glucose metabolism and inhibiting NOX2.",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,2021
